[Efficacy and tolerance of aniracetam in elderly patients with primary or secondary mental deterioration].

Rivista di neurologia Pub Date : 1991-05-01
V Canonico, L Forgione, C Paoletti, A Casini, C V Colonna, M Bertini, R Acito, F Rengo
{"title":"[Efficacy and tolerance of aniracetam in elderly patients with primary or secondary mental deterioration].","authors":"V Canonico,&nbsp;L Forgione,&nbsp;C Paoletti,&nbsp;A Casini,&nbsp;C V Colonna,&nbsp;M Bertini,&nbsp;R Acito,&nbsp;F Rengo","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The study was carried out on 60 patients (mean age 69.9 +/- 10.3 years) suffering from slight-moderate brain pathology primary or secondary to vascular forms. Patients were treated with 1500 mg/day per os of Aniracetam or placebo. Drug efficiency evaluation was performed utilizing the following psychometric tests: Blessed Scale, figures repetition test, Benton test, Corsi test, Rey test, Pieron test, phrases construction test, verbal fluency test. They were carried out during basal visit after two and four month treatment. In Aniracetam treated group the score showed a significant improving during the first and second control. In placebo treated group no change statistically considerable happened in any test. Aniracetam has proved to be a useful drug in slight-moderate brain decay treatment of the elderly.</p>","PeriodicalId":76494,"journal":{"name":"Rivista di neurologia","volume":"61 3","pages":"92-6"},"PeriodicalIF":0.0000,"publicationDate":"1991-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rivista di neurologia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The study was carried out on 60 patients (mean age 69.9 +/- 10.3 years) suffering from slight-moderate brain pathology primary or secondary to vascular forms. Patients were treated with 1500 mg/day per os of Aniracetam or placebo. Drug efficiency evaluation was performed utilizing the following psychometric tests: Blessed Scale, figures repetition test, Benton test, Corsi test, Rey test, Pieron test, phrases construction test, verbal fluency test. They were carried out during basal visit after two and four month treatment. In Aniracetam treated group the score showed a significant improving during the first and second control. In placebo treated group no change statistically considerable happened in any test. Aniracetam has proved to be a useful drug in slight-moderate brain decay treatment of the elderly.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[阿尼西坦对老年原发性或继发性精神恶化患者的疗效及耐受性]。
该研究对60例(平均年龄69.9±10.3岁)患有原发性或继发性血管性脑病理的患者进行了研究。患者每天服用1500毫克的阿尼西坦或安慰剂。采用下列心理测试进行药效评价:Blessed量表、图形重复测验、Benton测验、Corsi测验、Rey测验、Pieron测验、短语构建测验、语言流畅性测验。他们在治疗2个月和4个月后的基础访问中进行。阿尼拉西坦治疗组在第一次和第二次对照期间得分均有显著改善。在安慰剂治疗组,在任何测试中都没有显著的统计学变化。阿尼西坦已被证明是一种有效的药物在轻度中度脑衰退治疗老年人。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Inflammatory myopathies]. Refsum's disease. Striated sphincter and genital dysfunctions in multiple sclerosis patients: an electrophysiological approach [Antiphospholipid antibodies and cerebral ischemia]. [Cerebrovascular manifestations while taking combined estrogens and progestins for contraceptive purposes. Clinical cases].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1